Evidence map›Paper›PMID 31720393›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2018

Xpert MTB/RIF assay for the diagnosis of

Eyasu Ejeta, Getenet Beyene, Zegeye Bonsa, Gemeda Abebe

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Rifampicin-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2025
    Article
  9. Article
  10. Heliyon · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Tropical medicine and infectious disease · 2022
    Review
  16. A Saudi Arabian Public Health Perspective of Tuberculosis.International journal of environmental research and public health · 2021
    Review
  17. Article
  18. Magnitude ofInfection and drug resistance · 2021
    Article
  19. Review
  20. Rifampicin-ResistantInfection and drug resistance · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eyasu EjetaMycobacteriology Research Center, Jimma University, P.O.BOX: 378, Jimma, Ethiopia.
Getenet BeyeneDepartment of Medical Laboratory Sciences and Pathology, Faculty Health Sciences, Jimma University, P.O.BOX: 378, Jimma, Ethiopia.
Zegeye BonsaMycobacteriology Research Center, Jimma University, P.O.BOX: 378, Jimma, Ethiopia.
Gemeda AbebeDepartment of Medical Laboratory Sciences and Pathology, Faculty Health Sciences, Jimma University, P.O.BOX: 378, Jimma, Ethiopia.
Jimma University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe introduction of a new and rapid molecular diagnostic for tuberculosis (TB) and rifampicin resistance (RIF) in the national TB program has improved the diagnosis of TB by shortening the turnaround time and detecting the presence of RIF resistance in high TB and human immunodeficiency virus (HIV) settings such as Ethiopia. However, the implementation of this new diagnostic tool for the diagnosis of

methodInstitutional based retrospective study was conducted among presumptive TB patients diagnosed with GeneXpert assay in the last three years (2015-2017) in Gambella Hospital from May 1-30, 2017. The data were collected from GeneXpert registration book using standard data extraction sheet. The data were entered and cleared using EPI data 3.1 and then, exported and analyzed using SPSS version 20.0 statistical software package.

resultOf the 995 presumptive TB patients who received the GeneXpert test in the last three years, 20.0% (95% CI: 17.4-22.7) of them had proven MTB detection while 4.9% (95% CI: 2.2-8.1) had RIF resistance. The prevalence of RIF resistance was 2.3% and 14.3% among the new and retreated cases respectively. There was also a 35.5% TB/HIV co-infections. The odd of MTB detection was higher among 15-29 [AOR 2.17 (95% CI: 1.25- 3.76)] and 30-44 [AOR 2.35 (95% CI: 1.36-4.07)] year old participants. The figure was however significantly lower among female [AOR 0.64 (95% CI: 0.45-0.91)] and unknown HIV status [AOR 0.38(95% CI: 0.24-0.61)] participants of the study. In addition, the odd of RIF resistance was significantly low among HIV unknown case [AOR 0.14 (95% CI: 0.02-0.96)]. It was also learnt that there was progressively decline of invalid or error Xpert result from 4.7% to 2.0% in the course of the study period (X

conclusionThe study confirms the high prevalence of TB, RIF resistance and TB/HIV co-infection among the study participants. Age, sex, and HIV status of the study participants were predictor factors for MTB detection while HIV status was associated with RIF resistance. Therefore, the results of the study indicate that there is the need for collaborative and intensified prevention of TB and HIV in the study area. The ongoing supervision and mentoring to improve the performance of Xpert in the institution need to be promoted.

Indexed as

EthiopiaGambellaHIVRIFTuberculosisXpert

Identifiers

PMID31720393
PMCPMC6830166
OpenAlexW2808662552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.